CLINICAL ROLE -
First-in-Class Approved Anti-BCMA Therapy: Belantamab Mafodotin-blmf
Belantamab mafodotin-blmf (Blenrep; GlaxoSmithKline) is the first in its class anti-BCMA therapy to gain FDA approval.
Read More